Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1620-1629

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 5, 2015-05 ,pp. : 477-482

John Wiley & Sons Inc

Access to resources Recommend Favorite

Identification of pathologically favorable disease in intermediate‐risk prostate cancer patients: Implications for active surveillance candidates selection

By  

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1484-1491

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal Duration of Androgen Deprivation in Combination with Radiation Therapy for Japanese Men with High-Risk Prostate Cancer

By  

Urologia Internationalis, Vol. 87, Iss. 1, 2011-06 ,pp. : 28-34

Karger

Access to resources Recommend Favorite

Systematic review and network meta‐analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen‐deprivation therapy to reduce risk of fragility fractures

By  

BJU INTERNATIONAL, Vol. 121, Iss. 1, 2018-01 ,pp. : 17-28

John Wiley & Sons Inc

Access to resources Recommend Favorite